GlassScriptPhysician profile
Anne K Kassira
NPI 1174780951
$3,834.58
in general payments reported to CMS, 2019-2025
30 companies · $810 in 2025
The $810 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.23 · 2021: $125 · 2022: $617 · 2023: $1,038 · 2024: $1,178 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $867.32 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $623.59 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $463.26 | 2022-2025 | |
| Pfizer INC. | $284.78 | 2022-2025 | |
| Edwards Lifesciences Corporation | $156.52 | 2025 | |
| Heartflow, INC. | $142.78 | 2024 | |
| Amgen INC. | $123.83 | 2022-2025 | Repatha |
| Inspire Medical Systems, INC. | $115.36 | 2024-2025 | Inspire |
| Lantheus Medical Imaging, INC. | $115.29 | 2023 | Definity |
| Actelion Pharmaceuticals US, INC. | $102.04 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Sanofi-Aventis U.S. LLC | $95.52 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $86.73 | 2024 | Arcalyst |
| Boston Scientific Corporation | $85.06 | 2022-2025 | Bodyguardian |
| Janssen Pharmaceuticals, INC | $74.75 | 2021-2023 | Xarelto |
| Abiomed | $55.91 | 2023 | Impella |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.11 | 2022-2023 | Jardiance |
| Novo Nordisk INC | $51.32 | 2022-2024 | Ozempic, Rybelsus |
| Atricure, INC. | $47.37 | 2023 | |
| Philips North America LLC | $46.56 | 2022-2023 | |
| Amarin Pharma, INC. | $39.23 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.33 | 2019 | |
| Abbott Laboratories | $25.28 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.41 | 2022 | |
| Daiichi Sankyo INC. | $23.69 | 2023 | Injectafer |
| Baxter Healthcare | $21.48 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Scpharmaceuticals INC. | $19.51 | 2025 | |
| Inogen, INC. | $17.37 | 2022 | |
| Dynavax Technologies Corporation | $17.07 | 2025 | Heplisav-B |
| Kiniksa Pharmaceuticals, LTD. | $15.33 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $14.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Kassira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.